Table_1_Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF.docx by Yanhong Guo (270212)

“…Among those 247 patients with MHD, 211 patients were already in treatment with angiotensin converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARBs) before being treated with sacubitril/valsartan. We also performed an analysis to compare the differences between the 211 patients who had previously received ACEi/ARB treatment and the 36 patients who were sacubitril/valsartan naive.…”

A single systemic prophylactic treatment with CpG-C results in long-term reduction of metastatic burden in the brain. by Amit Benbenishty (6524375)

“…<p>(<b>a</b>) In the experimental metastasis models, we used the aECAi approach [<a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.2006859#pbio.2006859.ref032" target="_blank">32</a>] for injection of tumor cells (see <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.2006859#sec002" target="_blank">Methods</a>): a method that improves brain targeting and preserves cerebral hemodynamics. …”

PDLB - Balance Sheet by Nguyen Linh (19516642)

“…</p><p><br></p><p dir="ltr">ECIP capital: PDLB received $225M of ECIP capital, and the regulators assigned them the lowest possible dividend (0.5%) on this capital for the first year of payments (announced in June). If we assume PDLB continues to pay 0.5% on this preferred and they have a cost of preferred equity of 10%, then we can calculate the value of this $225M liability as just $11M, with the rest a write-up to equity.…”

Supplemental data of Glucocorticoid Dependent Mesenchymal Cell Differentiation is Required for Perinatal Lung Morphogenesis and Lung Function by Yan Xu (6655778)

“…Cells were pelleted, counted and 50,000 cells per sample prepared for ATAC-seq at a depth of ~1,000,000 reads per sample. …”